Lurasidone‐induced hyperosmolar hyperglycemic syndrome: A case report. Issue 3 (24th May 2022)

• Record Type: Journal Article
• Authors: Hanyu, Shota; Kojima, Yusuke; Murai, Toshiya; Kawashima, Hirotsugu
• Is Part Of: Neuropsychopharmacology reports. Volume 42:Issue 3(2022)
• Page Start: 377
• Page End: 379
• Publication Date: 2022-05-24
• Subjects: bipolar disorder -- Drug‐related side effects and adverse reactions -- Hyperglycemia -- Hyperglycemic hyperosmolar nonketotic coma -- Lurasidone hydrochloride.; Neuropsychopharmacology -- Periodicals; 615.78
• DOI: 10.1002/npr2.12259
• Languages: English
• ISSNs: 2574-173X

Abstract

Abstract: Introduction: Lurasidone has few metabolic adverse effects and is recommended as an alternative when other antipsychotic drugs considerably increase body weight or blood sugar concentrations. Case presentation: An 81‐year‐old man with bipolar disorder developed hyperosmolar hyperglycemic syndrome as a side effect of lurasidone. Routine monitoring of blood glucose concentrations led to the early detection and treatment of this disease, preventing life‐threatening complications. Discussion and conclusion: We describe a rare case of lurasidone‐induced hyperosmolar hyperglycemic syndrome. The mortality rate of this syndrome is estimated to be up to 20%. This rate is significantly higher than that of diabetic ketoacidosis (currently <2%). Although lurasidone is considered to have a low risk of raising blood glucose concentrations, symptoms of hyperglycemia must be evaluated and blood glucose concentrations should be monitored regularly.